The use of high dose laquinimod for the treatment of multiple sclerosis

摘要

Here, a method of treating a human patient suffering from multiple sclerosis or a human patient presenting clinically isolated syndrome; a method of treating a human subject by providing neuroprotection to the human subject; Human patients with multiple sclerosis or clinical by increasing time to confirmed disease progression, increasing time to confirmed recurrence, or reducing brain atrophy in human patients A method of treating a human patient presenting with a syndrome isolated in, comprising orally administering to said human patient a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof. A method is disclosed. The present invention also provides a human subject by providing neuroprotection to a human subject for use in treating a human patient suffering from multiple sclerosis or a clinically isolated human patient. Multiple sclerosis for use in treating or by increasing time to disease progression confirmed in human patients, increasing time to confirmed recurrence, or reducing brain atrophy About 1.2 mg of laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient suffering from or a clinically isolated human patient An oral unit dosage pharmaceutical form of is provided. [Selection figure] None